Clasp Therapeutics

Clasp Therapeutics is developing precision T cell engagers (TCEs) that target cancer cells harboring specific driver mutations like KRas by directing the immune system to destroy tumors based on mutant peptide markers displayed on cancer cell surfaces. The company's proprietary pHLAre molecules are designed to engage T cells with tumor cells while sparing healthy tissue, with a focus on treating cancers that have not responded to current immunotherapies.